Etoricoxib for pain management during thyroid surgery--a prospective, placebo-controlled study

Area of Science:

• Anesthesiology
• Pharmacology
• Surgical Pain Management

Background:

• Thyroid surgery can cause significant postoperative pain.
• Effective pain management strategies are crucial for patient recovery.
• Opioid analgesics are commonly used but associated with side effects.

Purpose of the Study:

• To evaluate the efficacy of etoricoxib in managing pain after thyroid surgery.
• To determine if etoricoxib has an opioid-sparing effect in the early postoperative period.

Main Methods:

• A double-blind, placebo-controlled, randomized trial was conducted.
• Sixty-nine patients undergoing thyroid surgery received either etoricoxib 120 mg or placebo orally 60 minutes preoperatively.
• Oxycodone was used as a rescue analgesic, and its consumption was monitored.

Main Results:

• Etoricoxib did not significantly reduce oxycodone consumption in the first 6 hours post-surgery (P = 0.072).
• A significant reduction in rescue analgesic use was observed between 7 and 24 hours post-surgery in the etoricoxib group (P = 0.039).
• The mean difference in analgesic need was 24% (95% CI -1 to 47%) in the later period.

Conclusions:

• Etoricoxib 120 mg demonstrates efficacy in pain reduction during the 7 to 24-hour period after thyroid surgery.
• Etoricoxib does not provide an opioid-sparing effect within the first 6 hours post-thyroidectomy.
• Further research may explore optimal timing or dosage for etoricoxib in surgical pain management.